Tel:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@anticorps-enligne.fr

Recombinant SARS-CoV-2 Spike S1 anticorps (RBD)

Reactivité: SARS Coronavirus-2 (SARS-CoV-2), SARS Coronavirus (SARS-CoV) ELISA, IF, Crys, SPR Hôte: Souris Chimeric CR3022 unconjugated Recombinant Antibody
N° du produit ABIN6953044
  • Antigène Voir toutes SARS-CoV-2 Spike S1 Anticorps
    SARS-CoV-2 Spike S1
    Type d'anticorp
    Recombinant Antibody
    Épitope
    • 12
    • 3
    • 2
    • 2
    • 1
    RBD
    Reactivité
    • 40
    • 6
    • 4
    • 3
    • 3
    • 3
    • 2
    • 2
    • 1
    • 1
    SARS Coronavirus-2 (SARS-CoV-2), SARS Coronavirus (SARS-CoV)
    Hôte
    • 16
    • 10
    • 4
    • 3
    • 2
    • 2
    • 2
    • 1
    • 1
    Souris
    Clonalité
    • 28
    • 9
    • 4
    Chimeric
    Conjugué
    • 35
    • 3
    • 1
    • 1
    • 1
    Cet anticorp SARS-CoV-2 Spike S1 est non-conjugé
    Application
    • 40
    • 8
    • 8
    • 7
    • 4
    • 4
    • 4
    • 4
    • 4
    • 3
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    ELISA, Immunofluorescence (IF), Crystallization (Crys), Surface Plasmon Resonance (SPR)
    Fonction
    Recombinant monoclonal antibody to COVID-19 & SARS-CoV S glycoprotein.
    Specificité

    The antibody CR3022 binds the amino acids 318-510 in the S1 domain of the SARS-CoV Spike protein as well as SARS-CoV-2 (COVID-19) Spike protein. The antibody also binds to P462L-substituted S318-510 fragments of the SARS spike protein. The binding epitope is only accessible in the "open" conformation of the spike protein (Joyce et al. 2020).

    While most S-protein RBD binding antibodies compete for antigen binding with ACE2, the CR3022 epitope does not overlap with the ACE2-binding site. It does thus not hinder binding of neutralizing antibodies. While CR3022 on its own exhibits only a weak neutralizing effect, it has been shown to synergize with other S-protein RBD binding antibodies to neutralize SARS-CoV. This effect still has to be confirmed in context with SARS-CoV-2 (Yuan et al. 2020).

    Réactivité croisée (Details)
    The anti-SARS-CoV-2 antibody CR3022 was originally discovered in a SARS patient, but it was shown to be a potent binder of SARS-CoV-2 spike protein (S1).
    Attributs du produit

    OriginalSpeciesName: Human

    OriginalFormat: IgG1

    Purification
    Protein A affinity purified
    Immunogène
    The original monoclonal antibody was generated by sequencing peripheral blood lymphocytes of a patient exposed to the SARS-CoV.
    Clone
    CR3022
    Isotype
    IgG2b kappa
    Top Product
    Discover our top product SARS-CoV-2 Spike S1 Anticorps primaire
  • Indications d'application
    This antibody (CR3022) binds to both SARS-CoV and SARS-CoV-2 with high affinity. The initial characterization of the binding of this antibody was performed by ELISA and indicates potential for the development of diagnostic assays, as both virus-capture assays, or as controls in serological assays measuring immune-responses to virus exposure. Human IgG1, IgG3, IgM and IgA isotypes are available to mimic antibody responses seen in COVID19 (Amanat et al. 2020). Human IgG2 is available to assess its yet unknown role in the response to SARS-CoV-2. The original human IgG1 version of the antibody works synergistically in combination with another non-competing SARS antibody CR3014 and is a potential candidate for passive immune prophylaxis of SARS-CoV infection (Meulen et al., 2006). The original antibody (human IgG1) was also reported to bind the 2019-nCoV RBD (KD of 6.3 nM). This antibody has been attributed a potential to be developed as a therapeutic agent, alone or in combination with other neutralizing antibodies for treatment of 2019-nCoV infections (Tian et al., 2020).
    Commentaires

    This chimeric mouse antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques.

    Restrictions
    For Research Use only
  • Format
    Liquid
    Concentration
    1 mg/mL
    Buffer
    PBS with 0.02 % Proclin 300.
    Agent conservateur
    ProClin
    Précaution d'utilisation
    This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
    Stock
    4 °C,-20 °C
    Stockage commentaire
    Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.
  • Antigène
    SARS-CoV-2 Spike S1
    Abstract
    SARS-CoV-2 Spike S1 Produits
    Synonymes
    anticorps E2, anticorps Surface Glycoprotein, anticorps S
    Classe de substances
    Viral Protein
    Sujet
    Spike protein, COVID19, COVID 19, S protein, SARS-CoV S protein, S glycoprotein, E2, Peplomer protein, Spike protein S1, SARS Coronavirus, SARS-CoV-2, SARS CoV 2, 2019-nCoV
    UniProt
    P59594
Vous êtes ici:
Support technique